Comparison of conventional time-intensity curves vs. maximum intensity over time for post-processing of dynamic contrast-enhanced ultrasound

European Journal of Radiology

Volumn 75, Issue 1, 2010, Pages

  Palmowski, Moritz ^a   Lederle, Wiltrud ^a   Gaetjens, Jessica ^a   Socher, Michaela ^b   Hauff, Peter ^c   Bzyl, Jessica ^a   Semmler, Wolfhard ^b   Günther, Rolf W ^a   Kiessling, Fabian ^a  

^a RWTH AACHEN UNIVERSITY   (Germany)

^b GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^c BAYER PHARMA AG   (Germany)

Author keywords

Angiogenesis; Dynamic contrast enhanced ultrasound; MIOT; Post processing; Therapy monitoring

Indexed keywords

ANGIOGENESIS; ANTI-ANGIOGENIC THERAPY; ANTIANGIOGENIC; BLOOD VOLUMES; CANCER THERAPY; CLINICAL PRACTICES; DYNAMIC CONTRAST; HISTOLOGICAL ANALYSIS; IMMUNOHISTOCHEMISTRY; LOWER VESSEL; MANN-WHITNEY; MICROBUBBLE INJECTION; MICROBUBBLES; POST PROCESSING; POST-PROCESSING TECHNIQUES; SMALL ANIMAL; STANDARD DEVIATION; STATISTICAL ANALYSIS; THERAPY MONITORING; TIME-INTENSITY CURVES; ULTRASOUND SYSTEM;

BLOOD; HEMODYNAMICS;

ULTRASONICS;

ANGIOGENESIS INHIBITOR; CYANOACRYLATE DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIANGIOGENIC ACTIVITY; ARTICLE; BLOOD VOLUME; CANCER THERAPY; CONTRAST ENHANCEMENT; CONTROLLED STUDY; DENSITY; DRUG MONITORING; FEMALE; HISTOLOGY; IMMUNOHISTOCHEMISTRY; INTERMETHOD COMPARISON; MICROBUBBLE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROSPECTIVE PAYMENT; SENSITIVITY ANALYSIS; SQUAMOUS CELL CARCINOMA; TUMOR XENOGRAFT; ULTRASOUND; VALIDATION PROCESS;

ALGORITHMS; ANGIOGENESIS INHIBITORS; ANIMALS; CARCINOMA, SQUAMOUS CELL; CELL LINE, TUMOR; CONTRAST MEDIA; FEMALE; HUMANS; IMAGE ENHANCEMENT; IMAGE INTERPRETATION, COMPUTER-ASSISTED; INDOLES; MICE; MICE, NUDE; MICROBUBBLES; PYRROLES; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; TREATMENT OUTCOME;

EID: 77953873752     PISSN: 0720048X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejrad.2009.10.030     Document Type: Article

References (20)

1. Mousa S.A., and Mousa AS. Angiogenesis inhibitors: current & future directions. Curr Pharm Des 10 (2004) 1-9
2. Ruegg C., Meuwly J.Y., Driscoll R., et al. The quest for surrogate markers of angiogenesis: a paradigm for translational research in tumor angiogenesis and anti-angiogenesis trials. Curr Mol Med 3 (2003) 673-691
3. Kiessling F., Jugold M., Woenne E.C., and Brix G. Non-invasive assessment of vessel morphology and function in tumors by magnetic resonance imaging. Eur Radiol 17 (2007) 2136-2148
4. Persigehl T., Bieker R., Matuszewski L., et al. Antiangiogenic tumor treatment: early noninvasive monitoring with USPIO-enhanced MR imaging in mice. Radiology 244 (2007) 449-456
5. Dawson P. Functional imaging in CT. Eur J Radiol 60 (2006) 331-340
6. Laking G.R., and Price P.M. Positron emission tomographic imaging of angiogenesis and vascular function. Br J Radiol 76 (2003) 50-59
7. Dietrich C.F. Comments and illustrations regarding the guidelines and good clinical practice recommendations for contrast-enhanced ultrasound (CEUS) - update 2008. J Ultraschall Med 29 (2008) 188-202
8. Fleischer A.C., Niermann K.J., Donnelly E.F., et al. Sonographic depiction of microvessel perfusion: principles and potential. J Ultrasound Med 23 (2004) 1499-1506
9. Lucidarme O., Kono Y., Corbeil J., et al. Angiogenesis: noninvasive quantitative assessment with contrast-enhanced functional US in murine model. Radiology 239 (2006) 730-739
10. Evelhoch JL. Key factors in the acquisition of contrast kinetic data for oncology. J Magn Reson Imaging 10 (1999) 254-259
11. Mendel D.B., Laird A.D., Xin X., et al. In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship. Clin Cancer Res 9 (2003) 327-937
12. Palmowski M., Huppert J., Hauff P., et al. Vessel fractions in tumor xenografts depicted by flow- or contrast-sensitive three-dimensional high-frequency Doppler ultrasound respond differently to antiangiogenic treatment. Cancer Res 68 (2008) 7042-7049
13. Olbrich C., Hauff P., Scholle F., et al. The in vitro stability of air-filled polybutylcyanoacrylate microparticles. Biomaterials 27 (2006) 3549-3559
14. Kiessling F., Krix M., Heilmann M., et al. Comparing dynamic parameters of tumor vascularization in nude mice revealed by magnetic resonance imaging and contrast-enhanced intermittent power Doppler sonography. Invest Radiol 38 (2003) 516-524
15. Derchi L.E., Martinoli C., Pretolesi F., et al. Quantitative analysis of contrast enhancement. Eur Radiol 9 (1999) 372-376
16. Kreitner K.F., Kunz R.P., Weschler C., et al. Systematic analysis of the geometry of a defined contrast medium bolus-implications for contrast enhanced 3D MR-angiography of thoracic vessels. Rofo Fortschr Geb Rontgenstr Neuen Bildgeb Verfahr 177 (2005) 646-654
17. Gwyther S.J., and Schwartz L.H. How to assess anti-tumour efficacy by imaging techniques. Eur J Cancer 44 (2008) 39-45
18. Miles K.A. Functional computed tomography in oncology. Eur J Cancer 38 (2003) 2079-2084
19. Krix M., Kiessling F., Farhan N., et al. A multivessel model describing replenishment kinetics of ultrasound contrast agent for quantification of tissue perfusion. Ultrasound Med Biol 29 (2003) 1421-1430
20. Wilson S.R., Jang H.J., Kim T.K., et al. Real-time temporal maximum-intensity-projection imaging of hepatic lesions with contrast-enhanced sonography. AJR Am J Roentgenol 190 (2008) 691-695